- Home
- TKNO vs RCKT Comparison
TKNO vs RCKT Comparison
Compare TKNO & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- RCKT
- Stock Information
- Founded
- TKNO 1996
- RCKT 1999
- Country
- TKNO United States
- RCKT United States
- Employees
- TKNO N/A
- RCKT N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- RCKT Health Care
- Exchange
- TKNO Nasdaq
- RCKT Nasdaq
- Market Cap
- TKNO 256.9M
- RCKT 328.6M
- IPO Year
- TKNO 2021
- RCKT N/A
- Fundamental
- Price
- TKNO $4.35
- RCKT $3.28
- Analyst Decision
- TKNO
- RCKT Buy
- Analyst Count
- TKNO 0
- RCKT 13
- Target Price
- TKNO N/A
- RCKT $12.96
- AVG Volume (30 Days)
- TKNO 224.0K
- RCKT 6.0M
- Earning Date
- TKNO 08-07-2025
- RCKT 08-07-2025
- Dividend Yield
- TKNO N/A
- RCKT N/A
- EPS Growth
- TKNO N/A
- RCKT N/A
- EPS
- TKNO N/A
- RCKT N/A
- Revenue
- TKNO $38,923,000.00
- RCKT N/A
- Revenue This Year
- TKNO $9.52
- RCKT N/A
- Revenue Next Year
- TKNO $15.20
- RCKT $108.43
- P/E Ratio
- TKNO N/A
- RCKT N/A
- Revenue Growth
- TKNO 11.40
- RCKT N/A
- 52 Week Low
- TKNO $4.00
- RCKT $2.19
- 52 Week High
- TKNO $10.37
- RCKT $22.01
- Technical
- Relative Strength Index (RSI)
- TKNO 43.35
- RCKT 51.17
- Support Level
- TKNO $4.22
- RCKT $2.88
- Resistance Level
- TKNO $4.94
- RCKT $3.74
- Average True Range (ATR)
- TKNO 0.29
- RCKT 0.27
- MACD
- TKNO -0.00
- RCKT 0.02
- Stochastic Oscillator
- TKNO 16.75
- RCKT 35.43
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.